

1 **Acknowledgements**

2 We thank the clinicians and staff of Bangladesh Thalassemia Samity and Hospital for their
3 assistance in specimen collection.

4

5 *Correspondence: Kaiissar Mannoor, address: Institute for Developing Science and Health
6 Initiatives, Mohakhali, Dhaka-1212, Bangladesh, E-mail: kaiissar@ideshi.org, Phone: +88-
7 01797440713

8

9 **Keywords:** Thalassemia, Transfusion Transmitted Infection, Immunochromatographic (ICT)
10 testing, HBV, HCV.

11

12

13

14

15

16

17

18

19

20

1 **Author's contribution**

2 KM and FQ theorized and designed the project. FAN and NS collected patient history. GSB,
3 AUZN, RS, MIUK and SKS performed the experiments. MAS, ZZ, SKQ and AKMEH were
4 involved in data analysis and curation. GSB, AUZN, MTI and SKS wrote the manuscript. Project
5 and manuscript were reviewed by SSQ and MRFS. KM gave final approval of the version to be
6 published.

7

8 **Conflict of interest**

9 The authors have declared no conflict of interest.

10

11

12

13

14

15

16

17

18

19

20

1 **Abstract**

2 Transfusion transmitted infections (TTIs) have remained a major deterrent to public health,
3 particularly among the patients with transfusion-dependent Beta thalassemia in developing
4 countries. Although proper donor selection through adoption of WHO-advised infection panel has
5 lowered the rate of infections, the multi-transfused patients are not free of risk. The present study
6 screened 148 transfusion-dependent Beta thalassemia patients to determine the frequency of HCV,
7 HBV and HIV using ELISA method. Among these patients, infected cases with HCV, HBV and
8 HIV were 13.51%, 3.37% and 0%, respectively. Moreover, 2% of the patients had co-infections
9 with both HBV and HCV. The percentage of infections in the patients with frequent transfusion
10 interval (≤ 30 days) was significantly higher ($P < 0.0005$) than that in the patients with less frequent
11 transfusion intervals (> 30 days). Immunochromatography (ICT)-based rapid test kits are usually
12 used to screen and confirm these infections in the blood of the patients. However, ICT-based tests
13 are not sensitive enough to detect the infections. So, a combination of both Nucleic Acid testing
14 (NAT) and serological testing are suggested to significantly reduce the risk of viral infections
15 during blood transfusion.

16

17

18

19

20

21

1 **Introduction**

2 Annually, million units of blood are collected from the donors worldwide as the blood transfusion
3 is integral to management of patients suffering from diverse diseases, particularly hematological
4 disorders. From a record of 2013, it has been seen that there were more than 112 million units of
5 blood donation all over the world that year.¹ Accordingly, transfusion transmitted infections (TTIs)
6 continue to be a major public health issue in many parts of the world and multi-transfused patients
7 of Thalassemia (a group of inherited hemoglobinopathies caused by mutations in the beta globin
8 chain of hemoglobin) are at a particularly increased risk of TTIs.^{2,3} These inherited blood disorders
9 generally occur in the countries of thalassemia belt including Mediterranean and portions of West
10 Africa, North Africa, Middle East and South Asian countries including Bangladesh, India, and Sri
11 Lanka.⁴ As the patients with thalassemia, especially the patients with beta thalassemia major
12 (BTM) and a group of patients with Hemoglobin E-beta thalassemia (EBT) are transfusion-
13 dependent and these patients are very much prone to transfusion-transmitted viral infections. After
14 heart failure, viral infections are the second most common cause of mortality and the foremost
15 cause of morbidity among the patients with thalassemia followed by patients with bacterial and
16 parasitic infections.⁵ Although hepatitis B virus (HBV), hepatitis C virus (HCV), human
17 immunodeficiency virus (HIV), West Nile virus (WNV), human T cell lymphotropic viruses I, II
18 (HTLV-I/II) had been reported most frequently, HCV and HBV had been known as the most
19 prevalent etiological agents of chronic viral hepatitis and hepatocellular carcinoma among the
20 thalassemia patients.⁶

21
22 In the developed countries, the TTIs risks have been virtually eliminated because of the careful
23 and efficient screening approaches.⁷ However, challenges in developing countries span the entire

1 blood safety chain from donor selection to post-transfusion surveillance and these risks are really
2 a burning question for public health development.⁸ Bangladesh lies in the global thalassemia belt
3 with around 9,176 new thalassemic patients each year⁹ and the patients with transfusion dependent
4 BTM and EBT undergo regular transfusions with varying degrees of frequencies of transfusions
5 in every 7 to 120 days. However, although it is mandatory, World Health Organization (WHO)–
6 recommended standards for donor blood screening are not always followed in developing
7 countries like Bangladesh due to resource limitations and occasional lack of consciousness.¹⁰ The
8 patients with transfusion dependent BTM and EBT in Bangladesh not only suffer from various
9 complications for the disease itself, but also due to the lack of proper screening methods of donor
10 blood, and thus transfusion-transmitted infections are threatening as ‘Silent killers’.¹¹

11
12 The minimization of the risks of TTIs highly depends on selection of safe blood donors through
13 screening of the blood using sensitive methods for pathogen detection and such precaution reduces
14 the risk of allogenic blood transfusion. However, transmission of diseases still occurs if there is
15 the inability of the test method to detect the disease in the ‘pre-seroconversion’ or ‘window’ phase
16 of their infections, immunologically variant viruses, non-seroconverting chronic or immune–silent
17 carriers and laboratory testing errors.¹² In the present study, the patients with thalassemia used to
18 visit Bangladesh Thalassemia Samity and Hospital for routine blood transfusion. In the hospital,
19 immunochromatographic tastings (ICTs) were usually performed to detect the presence of a
20 number of common infections in the blood of donors before every transfusion. However, these
21 ICT-based rapid diagnostic test (RDT) kits have not been validated using confirmatory approaches,
22 such as ELISA or molecular methods and usually the ICT-based methods have repeatedly
23 demonstrated low sensitivity and specificity to detect the major TTIs.^{12,13} The present study

1 investigated the frequency of HBV, HCV and HIV infections among transfusion-dependent beta
2 thalassemia patients of the Thalassemia Samity and Hospital using ELISA method with the aim to
3 explore the efficacy of RDT based screening method.

4

5 **Materials and Methods**

6 **Study participants**

7 The study enrolled a total of 148 patients with transfusion-dependent Beta thalassemia over a
8 period of 7 months from August 2017 to February 2018. These patients were in the age range of
9 2-46 years (90 patients were <18 years). They used to visit Bangladesh Thalassemia Samity and
10 Hospital for follow up examinations and blood transfusions. Both EBT and BTM patients
11 participated in the study and they were all differentially diagnosed by Hemoglobin capillary
12 electrophoresis. The study also included 30 healthy controls (aged 2-46 years) who did not have
13 any previous history of hemoglobinopathies or related blood disorders. Prior to sample collection,
14 a written informed consent was obtained from the adults as well as from the legal guardians of the
15 children (both for the patients and the controls). About 5.0 milliliters of blood were collected from
16 each participant in serum tubes using the standard venipuncture method and serum was separated
17 from the collected blood. In case of patients, blood was collected before transfusion. The study
18 was approved by National Ethics Review Committee (NERC) of Bangladesh Medical Research
19 Council (BMRC), Dhaka, Bangladesh.

20 **Donor blood screening**

21 The Bangladesh Thalassemia Samity and Hospital routinely use ICT kits (EXcEL®, USA) for
22 detection of HBV, HCV and HIV in the blood of donors before transfusion. The donor blood was

1 usually arranged from the hospital services or by the guardian of the patients through their personal
2 contacts or from various blood banks. Every ICT-dependent suspected donor was usually excluded
3 from the transfusion process.

4

5 **Detection of HBV, HCV and HIV in the blood of patients**

6 As the presence of Hepatitis B surface antigen (HBsAg) in the serum is a good indicator of HBV
7 infections, Bioelisa HBsAg 3.0 kits (Biokit, Barcelona, Spain) were used to detect HBsAg.
8 Bioelisa HCV 4.0 (Biokit, Barcelona, Spain) was used for qualitative detection of anti-HCV
9 antibodies in the sera of the patients. The HIV 1/2/O Antigen/Antibody EIA Test Kit (Acon
10 Laboratories, CA, USA) was used for the qualitative enzyme immunoassay-based detection of
11 HIV-1 P24 antigen and total antibodies (IgG, IgM and IgA) to HIV-1, HIV-2, and/or Subtype O
12 in human serum or plasma. These tests were performed in accordance with the manufacturers'
13 instructions provided with the kits. The color intensity of the final reaction mixture was measured
14 with an ELISA reader (LabSystems Multiskan, USA) at 450 nm.

15 **Statistical analysis**

16 We performed Two-tailed chi-square test (two by two table) using <http://www.openepi.com/> to
17 calculate the frequency of infections among the two transfusion interval groups (≤ 30 days and >30
18 days). Estimation of the relative risk ratio (RR) and odds ratio (OR) were done at 95% confidence
19 interval (CI). A P-value of less than 0.05 was considered significant.

20

21

1 **Results**

2 **Demographic characteristics of the patients**

3 In this study, 53.38% of the participants were males and 46.62% were females. There were both
4 BTM and EBT patients among the participants. We recorded different demographic information
5 of the patients like name, address, gender, height, weight, BMI as well as transfusion-related
6 information like age of first transfusion, transfusion interval and number, splenectomy etc. The
7 baseline information of the patients is given in the Table 1.

8 **Trend of infections among the patients**

9 A total of 22 patients (14.86%) with thalassemia were found to be infected (Male: N=12, 54.54%
10 and female: 10, 45.45%). Among these 22 infected thalassemia patients, we identified 19 (12.83%)
11 patients infected with either HBV or HCV and 3 (2%) of them had coinfections with both HBV
12 and HCV. Also, the number of patients infected with HCV (N=20, 13.51%) was higher than that
13 of HBV (N=5, 3.37%) (Table 2). Moreover, none of the patients was infected with HIV and all the
14 healthy controls were negative for HBV, HCV and HIV (data not shown).

15 **Relation of infection frequency with transfusion interval**

16 We categorized the patients into two groups based on their transfusion interval. One of these
17 groups had the transfusion interval ≤ 30 days, whereas the other had the transfusion interval of >30
18 days. In the more frequent (≤ 30 days) transfusion group, the number of virally infected patients (N
19 = 18, 25.35%) was found to be significantly higher (P-value < 0.0005 , RR = 1.945 [1.464 -2.585],
20 OR = 6.198 [1.983 -19.37]) than that of the less frequent (>30 days) transfusion group (N = 4,
21 5.19%) (Figure 1).

1 **Discussion**

2 In Bangladesh Thalassemia Samity and Hospital, effective screening processes for infections are
3 done before blood transfusion for the proper selection of donors. However, still we could identify
4 patients with either HBV or HCV or both. The most important question was why some of the
5 patients got infected albeit standard screening processes were followed before every transfusion.

6
7 In case of HBV, there were some asymptomatic donors who were in the ‘window period’ (i.e. the
8 early infection period when an immunologic test is non-reactive) without any expression of
9 HBsAg. Also, people with occult HBV (absence of HBsAg and the presence of HBV DNA in liver
10 tissues with or without HBV DNA in the serum) may remain undetected by traditional ICT kits.¹⁴

11 Previous study also showed that the sensitivity of ICT-based rapid tests was not higher enough to
12 detect hepatitis status of a donor and these kits might not detect certain prevalent serotypes of HBV
13 in any particular region.⁸ Detection of the HBV DNA by implementation of nucleic acid testing
14 (NAT) assays had been reported to shorten the core window period to reduce the residual risk.¹⁵

15 In this study, the number of patients infected with HCV was higher than that of HBV. It should
16 be noted here that although there were HBV vaccine coverage to some extent in Bangladesh, there
17 were still no HCV vaccine available yet.¹⁶ This may explain why there were more thalassemia
18 patients infected with HCV than with HBV. Rate of infection was found to be significantly higher
19 in the patients who had to undergo frequent transfusions which indicates that multi-transfused
20 thalassemia patients are more prone to infections. This is compatible with previous findings that
21 demonstrated that multiple transfusions receiving for a long period of time might cause
22 immunomodulation resulting in susceptibility to infections.⁷

1 In Bangladesh Thalassemia Samity and Hospital, sometimes ELISA methods are applied as a
2 confirmatory test after the donors are suspected as positives by ICT approach. Nevertheless,
3 previous study had shown that ELISA only could detect HBsAg, whereas real-time PCR could
4 represent infection status by detecting HBV-DNA.⁸ On the other hand, recombinant immunoblot
5 assay (RIBA) had more accuracy in detecting HCV.¹⁶ The multi-transfused patients with
6 thalassemia may face increased immune dysfunction in the presence of iron overload following
7 splenectomy, which makes them more susceptible to infections.¹⁷ Moreover, in case of emergency,
8 there is a common practice in Bangladesh of risky blood donations by professional donors without
9 any kind of testings who are mostly drug abusers.¹⁸ Although nowadays an effective awareness in
10 safe blood transfusions and iron chelation therapy have made the morbidity rate of patients with
11 transfusion-dependent Beta thalassemia lower, new complications like hepatocellular carcinoma
12 are taking hold in the patients with thalassemia, which may be due to carcinogenicity of iron
13 overload and chronic infections.¹⁹ Specially, the thalassemia patients who become co-infected with
14 both HBV and HCV are at a greater risk of cirrhosis and hepatocellular carcinoma compared to
15 the mono-infected patients.²⁰

16
17 Hence, there is no alternative of making blood transfusion process safer by proper selection of
18 voluntary healthy blood donors, along with NAT which reveals viral agents earlier in the ‘window
19 period’ than other immunoassays. Additionally, screening of HBV-DNA and HCV-RNA needs to
20 be practiced regularly to avoid any kind of risks during blood transfusions.¹⁷ Studies in India,
21 China and Saudi Arabia had reported that NAT-based detection methods for HCV and HBV could
22 tremendously improve the efficacy of screening for protecting blood recipient from TTIs.²¹⁻²³
23 Furthermore, introduction of HBV NAT in the USA, along with the HBV vaccination policy made

1 a substantial contribution to blood transfusion safety and decreased residual risk of HBV
2 infections.²⁴ In the UK, NAT has reduced the risk of HCV by 95% and that of HIV by 10%.²⁵
3 However, in case of very low levels of viremia, NAT might not be effective enough to detect the
4 infections. Despite the limitations, to ensure safe blood transfusion, combination of both NAT and
5 serological testing may significantly reduce the risk of viral infections during transfusion and thus
6 may improve the quality of life of the thalassemia patients.⁶

7
8 In this study, we could not compare between serological and NAT-based methods due to budget
9 limitations. Such a comparison could have been a concrete evidence for urging NAT-based
10 screening for blood transfusion in Bangladesh. Moreover, inclusion of other pathogenic organisms
11 in the screening panel could have provided us more information on the severity of the current
12 situation.

13
14 **Conclusion:**
15 The patients requiring frequent blood transfusion are more prone to HCV and HBV infections,
16 which can be attributed to unsafe transfusions. To give these patients good quality of life from
17 these preventable complications, efficient screening method for proper donor selection should be
18 adopted in Bangladesh. In addition, awareness should be built to ascertain a safe transfusion. Such
19 practices will ensure a safe blood transfusion for the patients suffering from other diseases and
20 save them from unwanted life-threatening complications.

21
22

1 **References:**

- 2 1. Menitove JE. What is it all about? *Transfusion*. 2017;57(S2):1585–7.
- 3 2. Vidja PJ, Vachhani JH, Sheikh SS, Santwani PM. Blood Transfusion Transmitted Infections
4 in Multiple Blood Transfused Patients of Beta Thalassaemia. *Indian J Hematol Blood*
5 *Transfus*. 2011 Jun;27(2):65–9.
- 6 3. Islam MT, Sarkar SK, Sultana N, Begum MstN, Bhuyan GS, Talukder S, et al. High
7 resolution melting curve analysis targeting the HBB gene mutational hot-spot offers a
8 reliable screening approach for all common as well as most of the rare beta-globin gene
9 mutations in Bangladesh. *BMC Genetics*. 2018 Jan 2;19(1):1.
- 10 4. Tahura S. Thalassaemia and other hemoglobinopathies in Bangladeshi children. "Imperial
11 Journal of Interdisciplinary Research (IJIR)". 2017 Oct 7;3:180–4.
- 12 5. Waheed U, Ahmed Kiani R, Anwar M, Asad M, Zaheer H. Epidemiology of Transfusion
13 Transmitted Infection among Patients with β -Thalassaemia Major in Pakistan. *Journal of*
14 *Blood Transfusion*. 2016 Jul 11;2016.
- 15 6. Vento S, Cainelli F, Cesario F. Infections and thalassaemia. *Lancet Infect Dis*. 2006
16 Apr;6(4):226–33.
- 17 7. Blanco S, Balangero MC, Valle MC, Montini OL, Carrizo LH, Gallego SV. Usefulness of
18 nucleic acid testing to reduce risk of hepatitis B virus transfusion-transmitted infection in
19 Argentina: high rate of recent infections. *Transfusion*. 2017;57(3pt2):816–22.

- 1 8. Pruett CR, Vermeulen M, Zacharias P, Ingram C, Tayou Tagny C, Bloch EM. The use of
2 rapid diagnostic tests for transfusion infectious screening in Africa: a literature review.
3 *Transfus Med Rev.* 2015 Jan;29(1):35–44.
- 4 9. Noor FA, Sultana N, Bhuyan GS, Islam MT, Hossain M, Sarker SK, et al. Nationwide carrier
5 detection and molecular characterization of β -thalassemia and hemoglobin E variants in
6 Bangladeshi population. *Orphanet Journal of Rare Diseases.* 2020 Jan 15;15(1):15.
- 7 10. Awan SA, Junaid A, Sheikh S. Transfusion Transmissible Infections: Maximizing Donor
8 Surveillance. *Cureus.* 2018 Dec 28;10(12):e3787.
- 9 11. Saeed M, Hussain S, Rasheed F, Ahmad M, Arif M, Hamid Rahmani MT. Silent killers:
10 Transfusion Transmissible Infections-TTI, among asymptomatic population of Pakistan. *J*
11 *Pak Med Assoc.* 2017 Mar;67(3):369–74.
- 12 12. Agarwal N, Chatterjee K, Coshic P, Borgohain M. Nucleic acid testing for blood banks: an
13 experience from a tertiary care centre in New Delhi, India. *Transfus Apher Sci.* 2013
14 Dec;49(3):482–4.
- 15 13. Bloch EM, Shah A, Kaidarova Z, Laperche S, Lefrere J-J, van Hasselt J, et al. A pilot
16 external quality assurance study of transfusion screening for HIV, HCV and HBsAG in 12
17 African countries. *Vox Sang.* 2014 Nov;107(4):333–42.
- 18 14. Laperche S, Francophone African Group for Research in Blood Transfusion. Multinational
19 assessment of blood-borne virus testing and transfusion safety on the African continent.
20 *Transfusion.* 2013 Apr;53(4):816–26.

- 1 15. Keechilot CS, Shenoy V, Kumar A, Biswas L, Vijayrajratnam S, Dinesh K, et al. Detection
2 of occult hepatitis B and window period infection among blood donors by individual
3 donation nucleic acid testing in a tertiary care center in South India. *Pathog Glob Health*.
4 2016 Dec;110(7–8):287–91.
- 5 16. Ahmed MU, Begum HA, Hossain T, Chakraborty P. Incidence of Common Transfusion
6 Transmitted Diseases Among Blood Donors. *Journal of Armed Forces Medical College,*
7 *Bangladesh*. 2009;5(1):4–6.
- 8 17. Choudhry VP. Hepatitis B and C Infections in Multitransfused Thalassemic Patients. *Indian J*
9 *Pediatr*. 2015 Mar 1;82(3):212–4.
- 10 18. Mollah AH, Nahar N, Siddique MdA, Anwar KS, Hassan T, Azam MdG. Common
11 Transfusion-transmitted Infectious Agents among Thalassaemic Children in Bangladesh.
12 *Journal of Health, Population and Nutrition*. 2003;21(1):67–71.
- 13 19. Moukhadder HM, Halawi R, Cappellini MD, Taher AT. Hepatocellular carcinoma as an
14 emerging morbidity in the thalassemia syndromes: A comprehensive review. *Cancer*.
15 2017;123(5):751–8.
- 16 20. Konstantinou D, Deutsch M. The spectrum of HBV/HCV coinfection: epidemiology, clinical
17 characteristics, viral interactions and management. *Ann Gastroenterol*. 2015;28(2):221–8.
- 18 21. Kumar R, Gupta S, Kaur A, Gupta M. Individual donor-nucleic acid testing for human
19 immunodeficiency virus-1, hepatitis C virus and hepatitis B virus and its role in blood safety.
20 *Asian J Transfus Sci*. 2015;9(2):199–202.

- 1 22. Dong J, Wu Y, Zhu H, Li G, Lv M, Wu D, et al. A pilot study on screening blood donors
2 with individual-donation nucleic acid testing in China. *Blood Transfus.* 2014 Apr;12(2):172–
3 9.
- 4 23. Alaidarous M, Choudhary RK, Waly MI, Mir S, Bin Dukhyil A, Banawas SS, et al. The
5 prevalence of transfusion-transmitted infections and nucleic acid testing among blood donors
6 in Majmaah, Saudi Arabia. *Journal of Infection and Public Health.* 2018 Sep 1;11(5):702–6.
- 7 24. Stramer SL, Notari EP, Kryzstof DE, Dodd RY. Hepatitis B virus testing by minipool
8 nucleic acid testing: does it improve blood safety? *Transfusion.* 2013;53(10pt2):2449–58.
- 9 25. Soldan K, Barbara J a. J, Ramsay ME, Hall AJ. Estimation of the risk of hepatitis B virus,
10 hepatitis C virus and human immunodeficiency virus infectious donations entering the blood
11 supply in England, 1993–2001. *Vox Sanguinis.* 2003;84(4):274–86.

12
13
14
15
16
17
18
19
20
21

1 **Table 1. Baseline information of the patients enrolled in this study**

Parameters	
Gender	Male, N=79 (53.38%); Female, N=69 (46.62%)
Thalassemia type	EBT, N=90 (60.81%); BTM, N= 58 (39.18%)
Age (years), mean \pm SD	17.15 \pm 9.33
BMI (kg/m ²), mean \pm SD	17.39 \pm 3.32
Transfusion interval (days), mean \pm SD	33.68 \pm 29.98
Transfusion number, mean \pm SD	228.32 \pm 189.85
Splenomegaly (cm), mean \pm SD	6.94 \pm 3.09
Splenectomy	N=21 (14.18%)

2 (Abbreviations: EBT= HbE Beta Thalassemia, BTM= Beta Thalassemia Major, SD= Standard Deviation, BMI= Body Mass Index)

3 **Table 2. Frequency of viral mono-infection and co-infection among the transfusion-**
 4 **dependent EBT and BTM patients**

Thalassemia type	Infection Type				No. of Total infected (%)
	No. of patients with HBV and HCV (%)	No. of patients with HBV (%)	No. of patients with HCV (%)	No. of patients with HIV (%)	
EBT (N=90)	1(1.11)	2(2.22)	11(12.22)	0(0)	14(15.55)
BTM (N=58)	2(3.44)	0(0)	6(10.34)	0(0)	8(13.79)
Total (N=148)	3(2.02)	2(1.35)	17(11.48)	0(0)	22(14.86)

5

- 1 (Abbreviations: EBT= E Beta Thalassemia, BTM= Beta Thalassemia Major, HBV= Hepatitis B Virus, HCV= Hepatitis C Virus, HIV= Human
- 2 Immunodeficiency Virus)

